- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03681600
Observatory of the Quality of Surgical Procedures for Digestive Cancers (Obchir)
Observatory of the Quality of Surgical Procedures for Digestive Cancers: Pilot Project.
Surgery for digestive cancers is managed according to quality standards, validated by the scientific community. Despite the diffusion of these standards through the benchmarks of good practice, the results of the surgery remain disparate.
In many countries, this "inequality of opportunity" has justified the establishment of quality assurance systems to measure the results of surgery for one or more localizations of digestive cancer.
These surgical audit experiments have shown a positive, rapid and cost-effective impact on complication rates, recurrence rates and overall survival even in the absence of interventional measures. The data collected also helped to improve the management of subgroups of patients usually excluded from clinical trials.
In Morocco, the National Cancer Prevention and Control Plan provides for the establishment of a quality assurance system with the introduction of a system for monitoring and evaluating the care of patients. This pilot project is part of this framework, for the group of patients who are candidates for surgery for digestive cancers.
Studieoversikt
Status
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Oujda, Marokko
- Regional center of oncology, surgical department
-
Rabat, Marokko, 10100
- Ibn Sina Hospital, Surgical department A
-
Rabat, Marokko, 10100
- Ibn Sina Hospital, Surgical department C
-
-
Please Enter The State Or Province
-
Rabat, Please Enter The State Or Province, Marokko, 10100
- National Institut of Oncology, Surgical oncology department
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- patients operated for a digestive cancer, proven or suspected, in a curative or palliative intent In elective situation: inclusion from surgery programming In emergent situation: inclusion no later than 72 hours after surgery
- Cancer proven or suspected in the following digestive tract: colon, appendix, anus, rectum, esophagus, stomach, eso-gastric junction, bile ducts, ampulla of Vater , pancreas, duodenum, small intestine and liver.
- Patient willing and able to agree to participate in the study
Exclusion Criteria:
Patient whose surgical intervention is indicated for:
- a condition that is not a digestive tract cancer, including whether retrospectively surgical exploration and / or histological examination reveals digestive localization cancer
- proven or suspected cancer of non-digestive location
- a proven or suspected cancer of peritoneal localization
- Patient whose surgical intervention is indicated for a progressive disease or a local recurrence proven or suspected of a digestive localization cancer having already been the resected (with the exception of situations of iterative liver resection for liver metastasis hepatic and recovery of the tumor bed after the discovery of vesicular cancer on cholecystectomy specimen)
- Patients whose intervention is for diagnostic purposes without any curative or palliative intention
- Patients whose surgery is a liver transplant
- Patients whose surgical intervention is local destruction (radiofrequency, microwaves) exclusively by percutaneous approach (without laparotomy or laparoscopy)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
90-day Mortality rate
Tidsramme: 90 days from surgery
|
Death within 90 days of surgical procedure
|
90 days from surgery
|
|
90-day Complication rate
Tidsramme: 90 days from surgery
|
Defined with by Clavien-Dindo grade I to IV within90 days of surgical procedure
|
90 days from surgery
|
|
3-year Overall survival
Tidsramme: from the date of operation to date of death from any cause, whichever came first, assessed up to 3 year
|
Overall survival is defined as time from initiation to death of any cause within 3years of surgical procedure
|
from the date of operation to date of death from any cause, whichever came first, assessed up to 3 year
|
|
3-year disease free survival
Tidsramme: from operation until recurrence of tumor or death from any cause, whichever came first, assessed up to 3 years
|
Disease free survival is defined as time from initiation to death of any cause within 3years of surgical procedure
|
from operation until recurrence of tumor or death from any cause, whichever came first, assessed up to 3 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Treatment decisions made within multidisciplinary team meeting / tumour board
Tidsramme: Prior to surgery
|
For every localization
|
Prior to surgery
|
|
Availability/performance of CT chest, abdomen and pelvis scan performed for pre-operative staging
Tidsramme: Prior to surgery
|
For every localization
|
Prior to surgery
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Amine Benkabbou, Pr, Moroccan Society of Surgery
- Hovedetterforsker: Raouf Mohsine, Pr, National institut of oncology
- Hovedetterforsker: Abdelmalek Hrora, Pr, Moroccan Society of Surgery
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- MoroccanSS
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .